Trials / Recruiting
RecruitingNCT04161053
Efficacy and Safety of Nitazoxanide in Preventing Recurrence of Hepatic Encephalopathy
Clinical Study Evaluating the Efficacy and Safety of Nitazoxanide in Preventing Recurrence of Hepatic Encephalopathy
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Tanta University · Academic / Other
- Sex
- All
- Age
- 20 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Efficacy and Safety of Nitazoxanide in preventing recurrence of Hepatic Encephalopathy.
Detailed description
Clinical Study Evaluating the Efficacy and Safety of Nitazoxanide in preventing recurrence of Hepatic Encephalopathy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rifaximin | Rifaximin 550 mg twice daily for 6 months |
| DRUG | Nitazoxanide | Nitazoxanide 500 mg twice daily for 6 months |
Timeline
- Start date
- 2018-11-01
- Primary completion
- 2028-11-01
- Completion
- 2028-12-01
- First posted
- 2019-11-13
- Last updated
- 2019-11-13
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT04161053. Inclusion in this directory is not an endorsement.